Tags: Nonalcoholic Steatohepatitis
Update on Clinical Trials for Nonalcoholic Steatohepatitis
Abstract: Tremendous effort has been put forth over the past 2 decades in understanding the pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Although multiple potential […]
Nonalcoholic Steatohepatitis Drug Development
Worldwide, the most common cause of chronic liver disease is now nonalcoholic fatty liver disease, which affects a quarter of the population. This disease is a […]
Drug Development for the Management of Nonalcoholic Steatohepatitis Cirrhosis
G&H What is the prevalence of cirrhosis in patients who have nonalcoholic steatohepatitis? NA Cirrhosis, or stage 4 fibrosis, is the last stage of the histologic […]
Genetics of Nonalcoholic Steatohepatitis
G&H What are the main genes involved with nonalcoholic steatohepatitis? AS There are a growing number of genes that have been linked both to the […]
Highlights in Nonalcoholic Steatohepatitis (NASH) From Digestive Disease Week 2020
A Review of Selected Presentations From DDW 2020 Obeticholic Acid Improves Experimental Non-Invasive Markers of Non-Alcoholic Steatohepatitis and Advanced Fibrosis: Results of a Secondary Analysis […]
Noninvasive Tests (NITs) in the Management of Nonalcoholic Steatohepatitis (NASH)
Abstract: Nonalcoholic fatty liver disease (NAFLD) affects approximately a quarter of the adult population in most Western countries, particularly those in Europe and North America. […]
Current Understanding of Risk for Nonalcoholic Steatohepatitis and Progressive Fibrosis
G&H What is the natural history of nonalcoholic steatohepatitis? MN Nonalcoholic steatohepatitis (NASH) is part of the disease spectrum of nonalcoholic fatty liver disease (NAFLD). […]
The Future of Treatment for Nonalcoholic Steatohepatitis
G&H How has nonalcoholic steatohepatitis traditionally been treated? MC No therapies have yet been approved by the US Food and Drug Administration (FDA) for the […]
Lifestyle Interventions Beyond Diet and Exercise for Patients With Nonalcoholic Fatty Liver Disease
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a growing worldwide concern, affecting approximately 30% of the US adult population. Developing pharmacologic therapies for NAFLD is […]
Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a spectrum of diseases ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) to advanced fibrosis and cirrhosis […]
Emerging Research on MGL-3196 for the Treatment of Nonalcoholic Steatohepatitis
G&H What is the mechanism of action of MGL-3196? ZY MGL-3196 (Madrigal Pharmaceuticals) is a thyroid hormone receptor β agonist. Thyroid hormone receptors can be […]
Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Abstract: Nonalcoholic fatty liver disease (NAFLD) affects 75 to 100 million adults in the United States and is the leading cause of chronic liver disease […]
Pharmacologic Management of Nonalcoholic Steatohepatitis
Abstract: Nonalcoholic steatohepatitis (NASH) is increasingly recognized as a major form of chronic liver disease in adults and children. Although improved dietary habits and regular […]
Overview of Current and Emerging Therapeutic Approaches to Nonalcoholic Steatohepatitis
G&H What role do diet and exercise play in the treatment of nonalcoholic steatohepatitis? SH Diet and exercise are the cornerstone of therapy for patients […]
Risk of Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis
G&H How common are nonalcoholic steatohepatitis and hepatocellular carcinoma in the United States, and how often do they coexist in a patient? MC Fatty liver […]
Gastro-Hep News
Inflammatory Bowel Disease Associated With Increased Risk of Myocardial Infarction Patients with inflammatory bowel disease (IBD), particularly women and patients between ages 20 to 25 years, […]
Gastro-Hep News
Committee for Medicinal Products for Human Use Votes for 8-Week Treatment Option for Hepatitis C Virus Infection On February 28, 2017, the Committee for Medicinal Products […]